Introduction
Leading Indian pharmaceutical firm can now launch a generic version of Risdiplam after Delhi High Court dismisses Roche’s appeal, enabling affordable treatment for Spinal Muscular Atrophy patients at ₹15,900 MRP.
Also Read: Eimco Elecon: Stock falls 12% after its net profits decline by 63% in Q2 FY26
Share price movement of Natco Pharma
On October 10, 2025, Natco Pharma Ltd opened at ₹841.05, up 3.35% from its previous close of ₹813.55. The stock reached a high of ₹862.65 and a low of ₹838.10. By 10:04 AM, it traded at ₹843.75, a 3.71% increase, with a market cap of ₹15,112.40 crore.
Delhi High Court Clears Natco’s Risdiplam Launch
Natco Pharma announced that the Commercial Appellate Division of the Delhi High Court dismissed Roche’s appeal against the launch of generic Risdiplam in India. The court’s decision was announced on October 9, 2025.
The judgment upheld an earlier ruling from March 24, 2025, which denied Roche’s injunction plea. This cleared the way for Natco to introduce a generic version of Risdiplam for Spinal Muscular Atrophy treatment.
Following the decision, Natco confirmed its immediate launch of Risdiplam in India at an MRP of ₹15,900. The company will also provide discounts to deserving patients through a special access program.
Ace investor holding in Natco Pharma
Akash Bhanshali holds a 1.01% stake in Natco Pharma Ltd, owning 1,800,788 shares valued at ₹151.8 crore.
Stock performance of Natco Pharma for Period of 1 week, 6 months, and 1 year
Natco Pharma Ltd delivered a -1.09% return over the past week, gained 4.91% in the past six months, and declined by 43.4% over the past year.
Also Read: NIBE: Stock in focus after receiving ₹29 Cr order for manufacturing and supply of gun stand
Shareholding pattern of Natco Pharma
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 49.50% | 49.60% | 49.60% |
| FII | 14.10% | 15.50% | 17.50% |
| DII | 5.90% | 5.80% | 5.60% |
| Public | 30.60% | 29.10% | 27.30% |
About Natco Pharma
Natco Pharma Ltd (NSE: NATCOPHARM) is a research-driven pharmaceutical company engaged in developing, manufacturing, and marketing complex products across finished dosage formulations, active pharmaceutical ingredients, and contract manufacturing for niche therapeutic areas in India.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Natco Pharma share price going up today?
A: Natco Pharma share price rose as Delhi High Court dismissed Roche’s appeal, allowing the launch of generic Risdiplam.
Q: What does Natco Pharma Ltd specialize in?
A: Natco Pharma Ltd specializes in developing, manufacturing, and marketing complex pharmaceuticals, including FDFs, APIs, and contract manufacturing.
Q: How much stake does Akash Bhanshali hold in Natco Pharma stock?
A: Akash Bhanshali holds a 1.01% stake in Natco Pharma stock, owning 1,800,788 shares valued at ₹151.8 crore.
